INOZYME PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
INOZYME PHARMA, INC. had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value of $751.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 · last filed 2025-03-10
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $751.00K.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $3.01M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $18.00K.
- 2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $741.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value |
|---|---|
| 2024-12-31 | $751.00K 10-K · filed 2025-03-10 |
| 2023-12-31 | $3.01M 10-K · filed 2024-03-12 |
| 2022-12-31 | $18.00K 10-K · filed 2023-03-22 |
| 2022-09-30 | $741.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.76M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.96M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.82M 10-K · filed 2022-03-15 |
| 2021-09-30 | $8.68M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $13.77M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $16.52M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $15.07M 10-K · filed 2021-03-25 |
| 2020-09-30 | $17.01M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $806.00K 10-Q · filed 2020-09-03 |
| 2019-12-31 | $452.00K 10-Q · filed 2020-09-03 |